A Modern vaccine (COVID-19) is seen at the LA Mission homeless shelter on Skid Row in Los Angeles, California, USA, February 10, 2021.
Lucy Nicholson | Reuters
Moderna said Thursday that it expects to generate $ 18.4 billion in sales of its Covid-19 vaccine this year.
Publishing its fourth-quarter earnings, Moderna also said that its medical director, Tal Zaks, will leave the company at the end of September. The company said it has hired Russell Reynolds “to hire a new CMO with global and business experience.”
Moderna’s shares rose 3.9% in premarket trading.
The news comes a day after the company said it expected to produce at least 700 million doses of Covid vaccine this year. It also said it expects to produce up to 1.4 billion doses of Covid vaccine in 2022.
Pfizer, which also has a vaccine licensed for use in the United States, said earlier this month that it expected to sell about $ 15 billion in doses this year.
Moderna has an agreement with the federal government for 300 million doses and has shipped about 55 million doses to the US It expects to complete delivery of the first 100 million doses to the US by the end of the first quarter. , the second 100 million doses for the end of May and the third of August.
Moderna, like other vaccine manufacturers, has been working rapidly to meet demand for vaccines that will hopefully help end the pandemic, which has infected more than 112 million people and killed at least 2 , 4 million, according to data compiled by Johns Hopkins. University.
The company is in talks with the Food and Drug Administration about a proposal to fill its Covid vaccine vials with up to five additional doses to alleviate a manufacturing bottleneck. A vial of Moderna’s two-shot vaccine contains 10 doses, enough to inoculate five people, according to the Centers for Disease Control and Prevention.
The company also said Thursday that it is in talks with the World Health Organization-backed COVAX initiative to deliver doses this year and in 2022.
Moderna’s vaccine has been cleared by the FDA for use in people over 18 years of age. Clinical trial studies are incomplete for children, whose immune systems may respond differently from adults.
The company said Thursday it completed enrollment of 3,000 participants in a clinical trial testing its vaccine in children ages 12 to 17.